Polymorphism specifying the diversity of nature is widely observed in pharmaceutical compoundsDifferences in their physico-chemical and mechanical properties led to the emergence of characterization based stringent quality control measures of these altered solid-state forms, in active pharmaceutical ingredients (APIs) and drug products, both during filing of New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs)